IGF2BP2 and neoplasm: A similar risk signature (ALKBH5, IGF2BP2, IGF2BP3, HNRNPA2B1, YTHDF1, YTHDF2, RBM15, and WTAP) was shown to be prognostic for glioma patients, and the expression of IGF2BP2 and IGF2BP3 was linked to tumour occurrence, development, and progression [206].